Back to top anchor

Silencing oncogenic signalling in hypoxic tumour cells with the prodrug PR610

42 months
Approved budget:
Associate Professor Adam Patterson
Health issue:
Cancer (oncology)
Proposal type:
Lay summary
Scientists in New Zealand have invented an exciting new chemotherapy compound with huge potential to treat cancer. The compound, called PR610, is a 'stealth' prodrug that can deliver high concentrations of an anti-cancer agent to tumours while avoiding normal tissues. It appears to be much more active than traditional chemotherapy without the usual side effects. PR610 has shown remarkable activity in the laboratory and is currently undergoing safety trials in New Zealand hospitals and the USA. The exact mechanisms underlying the promising anticancer activities of PR610 are unknown. Through this study, we hope to reveal the important features of PR610's design to inform clinical development and aid the design of future agents in this class. In addition, the vast potential for combining PR610 with other standard treatments such as radiotherapy and monoclonal antibodies will be evaluated. This could lead to widespread adoption of PR610 in modern oncology practise.